Seeking Alpha
  • Is The Elixir Of Youth Closer Than We Think? A New Way Of Viewing Blood Products Companies
    BAX, BMY, CSLLY Today, 11:18 AM Keith Williams Comment!

    Summary

    • Parabiosis reveals young blood reverses ageing effects; potential implications for blood plasma companies?
    • Blood product companies (Grifols, CSL, Baxter) have everything in place to fast track a plasma-based product.
    • Grifols invests in startup Alkahest to develop (young) plasma based products for aging/neurodegeneration.
    • Another approach to aging involves combination of two drugs (Dasatinib and Quercetin) to attack senescent cells (Senolytics).
  • Deutsche Annington Immobilien SE: Why You Should Be Cautious
    DAIMF Today, 11:18 AM Armin Satzger Comment!

    Summary

    • Deutsche Annington's image and perception among tenants - and in the public - is not good, due to the bad shape of its rental objects and the service quality offered.
    • Tightened regulation measures reduce potential profits for real estate companies in Germany.
    • The real estate market is vulnerable to major market corrections.
    • Risks for U.S.-based investors rise with increasing volatility in the EUR/USD exchange rate and with the ECB's QE program.
  • Allstate Leads On Sustainability Metrics
    ALL Today, 11:16 AM Katherine Schrank Comment!

    Summary

    • Allstate leads among its peers for environmental and social disclosures valued by the capital markets.
    • Since 2007, Allstate has disclosed the risks that climate change poses to its financial performance, its customers, and its operations - and, how they are managing those risks.
    • Allstate leads among its peers on gender diversity metrics, with women comprising 27% of its board, which may validate recent studies that correlate board diversity with strong financial performance.
  • Ford: Can A Lincoln Rebirth Throw Sales Into Overdrive?
    F Today, 11:04 AM Orange Peel Investments 2 Comments

    Summary

    • American luxury has struggled post-2008; including Buick, Cadillac and Lincoln.
    • Ford announced plans to reinvent the Lincoln Continental, last produced in 2002.
    • This should help drive Asia profits as the Chinese have an appetite for American luxury.
  • Growth In U.S., PSAI Turnaround, And EM Momentum Are Bullish For Dr. Reddy's In FY16
    RDY Today, 11:04 AM stockguru Comment!

    Summary

    • US remains the key growth driver with around 40% of sales.
    • Dr. Reddy's has 68 ANDAs pending approvals (including 43 para IVs and 13 FTFs) addressing US$36B of innovator brand value.
    • Dr. Reddy’s has been stepping up investments in complex generics, biosimilars and proprietary products to drive growth beyond 2020.
  • ModernGraham Quarterly Valuation Of Western Digital Corporation
    WDC Today, 10:59 AM Benjamin Clark 1 Comment

    Summary

    • WDC is suitable for both the Defensive Investor and the Enterprising Investor following the ModernGraham approach.
    • According to the ModernGraham valuation model, the company is undervalued at the present time.
    • The market is implying a 3.24% earnings growth over the next 7-10 years, which is significantly less than the rate the company has seen in recent years.
  • Wolfcamp Acreage And Cost-Cutting Moves Will Help Pioneer Natural Resources Get Better
    PXD Today, 10:58 AM Amal Singh Comment!

    Summary

    • Pioneer Natural Resources has outperformed the broader market this year as its net income has improved despite the weakness in crude oil prices.
    • Crude oil prices should improve due to an expected rebound in the Chinese economy and the onset of the driving season in the U.S., creating a tailwind for Pioneer.
    • Pioneer has created feeder lines for supplying brackish water to its wells, and this has helped the company save around $150,000 per well in Southern Wolfcamp.
    • The sheer size of the Wolfcamp shale will allow Pioneer to expand its production at a good pace in the long run.
  • Vale: Forget The Noise And Think Long Term
    VALE Today, 10:58 AM Conrado Foglio Bonda 1 Comment

    Summary

    • The S11D project is a game changer for Vale.
    • BRL depreciation will have a favorable impact on both Capex and Opex.
    • 2015 will be very difficult in terms of FCF but long-term prospects are intact.
    • Focus on the fundamentals and on the underlying business and forget about the noise.
  • InsiderInsights.com Daily Round Up 3/30/15: VEEV, VNCE, PRSS, OGS
    AET, ALCO, ARMK Today, 10:55 AM InsiderInsights Comment!

    Summary

    • Tables of the top insider purchases and sales filed with the SEC on 3/30/15, based on dollar value.
    • Dollar values often do not equate with significance when it comes to insider trades.
    • Proprietary Insider Company Ratings are relayed to clarify significance.
  • The Finish Line: Heavy Dependence On Nike Poses Serious Vendor Concentration Risk
    FINL Today, 10:50 AM Henry Cao Comment!

    Summary

    • Vendor concentration risk: 70% of merchandise comes from Nike.
    • Lack of innovation in the running segment poses significant margin headwinds.
    • Foot Locker and e-commerce players create increasing competitive landscape.
    • Recommendation: Sell (DCF valuation: 20.71).
  • UnitedHealth Opens New Front On Express Scripts With Catamaran Buy
    UNH Today, 10:46 AM Dana Blankenhorn Comment!

    Summary

    • UnitedHealth gets better control of its drug costs by buying another large Pharmacy Benefit Manager.
    • Express Scripts, the largest player, now faces a new competitive landscape.
    • Expect more mergers in the medical channel.
  • Amarin: A Look At The Recent Selloff And Negative Perceptions
    AMRN Today, 10:42 AM Clinically Sound Investor 2 Comments

    Summary

    • Should Investors Toss in the Towel on Motley Fool's Feature on Amarin? Read on to find out why Amarin is not a "sell" that MF portrays.
    • Vascepa gains market share for total prescriptions and refills on a down week.
    • A ruling on the NCE suit is upcoming.
  • Apple: What's A Proper Buyback?
    AAPL Today, 10:41 AM Bill Maurer 3 Comments

    Summary

    • Investors expect company to raise buyback for third straight year.
    • Size of raise most likely depends on time frame for execution.
    • Domestic cash buffer around $20 billion is key for debt raises.
    • Flexibility is key, so smaller buyback may be best solution.
  • STMicroelectronics Not Fit To Take On The Competition
    STM Today, 10:29 AM EST Invest Comment!

    Summary

    • Declining revenue has become the dominant trend for the company over the years.
    • Foreign and domestic competition hurting margins and the market share.
    • The company lacks proper moat due to standard product line.
  • Best Buy's Move To Axe A Canadian Subsidiary Is A Bullish Sign
    BBY Today, 10:24 AM Jayson Derrick Comment!

    Summary

    • Best Buy Co Inc announced it will close 66 Future Shop stores and convert another 65 in to Best Buy stores.
    • Best Buy's International segment, while small, still represents a significant opportunity.
    • Now that Best Buy has turned around its domestic operation, management can focus elsewhere.
  • Qunar: Will The Flight Higher Continue?
    QUNR Today, 10:22 AM Brian Nichols Comment!

    Summary

    • QUNR has been a Wall Street favorite for Chinese technology stocks in recent months.
    • While growing fast, the company is priced very high, and has some legitimate questions attached to its business right now.
    • Therefore, is the risk worth the reward?
  • Genfit: Misunderstandings And Propaganda About Phase 2b Results Provide A Good Entry Point
    GNFTF Today, 10:10 AM Logribel Biostocks 5 Comments

    Summary

    • After the release of its phase 2b preliminary results in NASH, Genfit’s stock saw a nearly 45% decline following extremely negative interpretations of its results.
    • With a cool head and some analytical perspective, I believe that Genfit’s results fell victim to a widespread misinterpretation and offer great perspective in NASH.
    • When compared against its biggest competitor’s drug, Intercept’s OCA, Genfit’s GFT505 demonstrates very good efficacy results and a much better safety profile.
    • After Friday’s sell-off, which I believe is unjustified, Genfit still presents an excellent investment opportunity and current share price is a very good entry point.
  • Vivus Offers Operational Update - Is Trouble Brewing?
    VVUS Today, 10:02 AM Spencer Osborne 2 Comments

    Summary

    • Company re-tasks sales force.
    • Company negotiating with FDA to reduce cost of Trials for Qsymia.
    • Company focus will be on digital advertising.
  • Headwaters Incorporated: Growth Spurt Not Over
    HW Today, 10:01 AM Eric Harding Comment!

    Summary

    • 8% increase in February of new single-family homes will help the company make a case for its fly ash concrete, which is rapidly growing in popularity.
    • Optimistic data from the home remodeling industry should give a boost to Headwaters’ light building products segment.
    • Strong Q1 results indicate that we should see continued growth in Q2.
    • Healthy financials make Headwaters a solid growth play for 2015.
  • Google Is Positioned To Dominate The VR/AR Market
    GOOG, GOOGL Today, 10:01 AM Lior Ronen 4 Comments

    Summary

    • Virtual and Augmented Reality return to our lives from the 90s.
    • VR/AR is one of the hottest evolving technology markets with many tech giants trying to penetrate it.
    • Google executes its strategy from another consumer electronic market in order to lead the market.
  • Update On Nortek: Boring But Well-Performing And Well-Managed Business
    NTK Today, 10:00 AM Stanislav Ermilov Comment!

    Summary

    • Growth in underlying construction markets is confirmed by the recent data.
    • Further acquisitions and their effective integration drive EBITDA growth further.
    • NTK stands to benefit from fixed operating cost leverage and sizable cost structure improvements.
  • Why Oasis Petroleum Looks Like A Good Bet In A Weak Oil Price Environment
    OAS Today, 9:58 AM Harsh Singh Chauhan Comment!

    Summary

    • More than 50% of Oasis' expected 2015 production is hedged at a price of $88 per barrel, and this will protect the company from any further downside in oil prices.
    • Oasis Petroleum has built up a strong production profile with low well costs, which is why it will need to spend 12% less on capex this year.
    • Despite weak crude oil pricing, Oasis' return on equity, cash flow, and EBITDA have improved, signifying the resilience of its operations.
  • Winnebago Industries - Short-Term Headwinds, Long-Term Appeal
    WGO Today, 9:56 AM The Value Investor 5 Comments

    Summary

    • Winnebago Industries continues to see margin pressure following tight labor conditions and strategic investments.
    • Accelerating sales growth and prospects for margin stabilization could improve appeal going forwards.
    • Long-term tailwinds, a fairly appealing valuation and strong balance sheet drive appeal if margins stabilize.
  • MannKind Valuation Scenarios
    MNKD Today, 9:50 AM US Investor 38 Comments

    Summary

    • Afrezza revenues need to catch up fast.
    • Market is already pricing in a blockbuster drug.
    • Afrezza accounts for most of MannKind's net worth.
  • Despite Fundamental Challenges, Cabot Oil & Gas Is A Good Long-Term Bet
    COG Today, 9:49 AM Renu Singh Comment!

    Summary

    • Cabot Oil & Gas has a very weak balance sheet, but the company is deliver better cash flow and an improvement in its gross margin.
    • Cabot's margin should improve further as it will spend 44% less on capital expenses this year, but still deliver growth in production.
    • Cabot's investments in the Eagle Ford and Marcellus Shale plays will enable it to benefit from an improvement in the price of natural gas and oil.
    • Cabot's earnings are expected to increase at twice the industry average in the next five years.
  • Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients
    NWBO Today, 9:48 AM Smith On Stocks 12 Comments

    Summary

    • These 51 patients were screened for the phase 3 trial of DCVax-L, but their cancers progressed before they could be enrolled and they were treated on a compassionate use basis.
    • They received the exact same treatment, from the same institutions, and their data was subjected to the same independent review processes as the patients enrolled in the phase 3 trial.
    • Median overall survival in this open label, non-randomized trial was 15.3 months; rapid progressors showed an increase of 5 to 8 months when compared with historical controls.
    • In this most aggressive stage of glioblastoma, durable effects were seen as 30% of patients were alive after 2 years, and 5 for about 3 years or more.
    • This data increases expectations for the DCVax-L success in the healthier, newly diagnosed patients enrolled in the ongoing, blinded, randomized phase 3 trial.
  • CoStar Group Doesn't Need A Strong Commercial Property Market To Thrive
    CSGP Today, 9:43 AM Alpha Gen Capital Comment!

    Summary

    • CoStar has a unique and highly defensible business with strong leverage to the commercial property and apartment rental listing channel.
    • A strong focus on investing in the future including revamping the new Apartments.com and LoopNet businesses to tiered pricing appears to be working.
    • CoStar should capitalize on the emerging recovery in the commercial real estate markets in Asia and Europe as well as strong continued traction in the US commercial market.
  • Foreign Currency Movements Remain Main Factor To Influence Top, Bottom-Line Growths
    AVP, CL, GIS Today, 9:40 AM Equity Watch Comment!

    Summary

    • Strengthening of U.S. dollar will weigh on top and bottom-line growths of companies with international market operations.
    • Euro will continue to depreciate against U.S. dollar.
    • Fed’s inclination towards increasing interest rates will strengthen U.S. dollar versus other important currencies.
  • Rand Worldwide: Undiscovered Micro Cap With A Value Creating Chairman
    RWWI Today, 9:32 AM The Enterprising Value Investor 2 Comments

    Summary

    • Rand Worldwide is a solid business with attractive FCF characteristics.
    • Despite the market partially pricing in the effects of the tender offer, Rand's shares remain significantly undervalued due to the firm's small size and limited trading volume.
    • The Chairman of RWWI is Peter Kamin, a terrific value investor with an enviable track record of unlocking value for shareholders.
  • Apple: Becoming A Semiconductor Powerhouse
    Editors' Pick AAPL Today, 9:32 AM Mark Hibben 15 Comments

    Summary

    • Apple's iOS devices all use Apple's custom processors.
    • Because of the explosive growth of its mobile devices, Apple has become one of the world's largest semiconductor companies.
    • Apple's semiconductor prowess will make it possible to build ARM-based Macs at lower cost and higher margin than with Intel Inside.
    • This economic imperative will mandate a Mac transition to ARM beginning in 2016.
  • Rosetta Stone: Make A Profit By Putting Your Ego Aside
    RST Today, 9:24 AM Tal Davidson 1 Comment

    Summary

    • Rosetta Stone is pivoting its strategy again, focusing on enterprise and education, pulling out of the consumer segment and engaging in extreme cost cutting. The strategy is viable.
    • The price is attractive, factoring in only a very modest success. A double or a triple is not a remote scenario.
    • Activist investor David Nierenberg, possibly with the cooperation of Osmium Partners, recently drove CEO Swad to resign. Their commitment to RST's success is an important factor in the transformation.
  • Qorvo: You Can Benefit From The Growth Of RF
    Editors' Pick QRVO Today, 9:22 AM Focus Equity 1 Comment

    Summary

    • Qorvo Inc. is exposed to the growth prospects of RF products in mobile, communication infrastructure, and defense.
    • Consolidation of RFMD and TriQuint can result in synergistic benefits including cost reductions and favorable pricing amid limited number of suppliers in the industry.
    • Relative valuation and EVA indicate that the stock is underpriced. Hence, we rate Qorvo as a buy.
  • Wabtec: Expensive But Still Attractive
    WAB Today, 9:09 AM Michael Boyd Comment!

    Summary

    • Rail industry, especially US rail, has been an incredibly resilient industry.
    • Wabtec has substantial cash generation, feeding the acquisition machine.
    • If investors get scared by Wabtec's valuation, they still need some sort of rail exposure.
  • Endeavour Silver Eases My Concerns
    EXK Today, 9:03 AM Christopher F. Davis 1 Comment

    Summary

    • I recently wrote an article that described many of the concerns I had with Endeavor Silver, including declining production and rising costs for 2015.
    • After being contacted by Investor Relations and discussing a new initiative my concerns have been somewhat allayed.
    • The operating environment is difficult and hopefully the CEO interview will ease not just more of my one, but investors' concerns as a whole.
  • This Stock Needs To Be On Your Radar For 2015: Omega Flex
    OFLX Today, 8:56 AM Nicholas Bodnar Comment!

    Summary

    • 76% of the shares are held by insiders making the stock's liquidity too low for most institutional investors.
    • ROE, ROA and Gross Profit margins of 45%, 27% and 58% respectively.
    • The stock is a little pricey based on EV/EBITDA and P/E as of right now. There is downward pressure that may make the stock undervalued in the near future.
  • Adamis: An Easy Double After The FDA's CRL, With Even More Long-Term Growth Potential
    ADMP Today, 8:50 AM Bridging the Gap 10 Comments

    Summary

    • Adamis's shares tanked 35% in after-hours trading on Friday, March 27, because of the FDA issuing a CRL for the company's lead drug, the Epinephrine pre-filled syringe.
    • This drop was due to investor worries that the company's current cash reserves cannot sustain it through the 6 months needed for the FDA to re-review its NDA.
    • However, the company can obtain cash in multiple ways, including a secondary offering, a private financing deal, or a partnership with a large biotech.
    • Friday's move was a major overreaction, as shares are now trading at the same levels as last August, despite the company having had numerous positive events happen since that time.
    • Adamis is also exceptionally undervalued based on product potential, with the conservative valuation of just its lead drug worth 5x the current market cap.
  • Ex-Watergate Prosecutor Appointed To Probe Caesars' Bankruptcy
    CZR Today, 8:48 AM Shock Exchange Comment!

    Summary

    • A bankruptcy judge appointed an ex-Watergate prosecutor to examine inter-company asset transfers at Caesars.
    • Caesars' main operating subsidiary, CEOC, transferred assets to Caesars Growth Partners in October 2013 and May 2014.
    • CEOC was placed into bankruptcy in January 2015. I estimate its fair value to be far less than its $18 billion debt load.
    • If the asset transfers were deemed to rob debt holders, a prosecutor may require the transactions to be unwound.
    • The investigation does not bode well for Caesars' shareholders.
  • Celladon: The Next Breakthrough In Cardiovascular Gene Therapy?
    CLDN Today, 8:48 AM DoconStocks 10 Comments

    Summary

    • Celladon’s main focus is on MYDICAR which has the potential to be a blockbuster drug for cardiovascular therapy.
    • Celladon has been assigned Breakthrough Designation by the FDA, and could receive approval fairly quickly if the CUPID 2 study results demonstrate excellent efficacy as well.
    • Current cardiovascular treatments are limited, allowing Celladon to leave a mark in the space early and lead the way for future treatments.
  • Ultra Petroleum - High-Margin Gassy Player
    UPL Today, 8:32 AM Steve Zachritz 1 Comment

    Summary

    • Low costs and strong realized prices = superior margins.
    • Likely cash flow neutral (or better) in 2015.
    • Leverage is elevated but not overtly so.
    • Stock weighed on by gassy group sentiment, but expect margins to standout after the shoulder season.
  • Buy The Dip In Sonic Corp
    SONC Today, 8:23 AM Jayson Derrick Comment!

    Summary

    • Shares of Sonic Corp plunged after the company reported its second quarter results.
    • Shares were trading at 52-week highs of $36.73 leading in to the print.
    • A sizeable dip in share price represents an attractive opportunity for investors.
  • TNT Express Is A Cheap Stock With Great Value Funds On Board
    TNTEF Today, 8:04 AM Holmes_Osborne Comment!

    Summary

    • The stock is very cheap at this point.
    • The merger in 2013 with UPS was blocked by the EU.
    • Three great value funds are major shareholders.
  • Deckers Outdoor Vs. Nike: Where Are Investors Better Off Putting Their Money?
    DECK, NKE Today, 7:55 AM Daniel Jones 1 Comment

    Summary

    • In recent years, Deckers has grown its sales at a nice pace, outperforming Nike, but when it comes to profit, costly expansion for Deckers leaves it behind its peer.
    • While this may appear to make Nike a better play, investors should consider that Deckers' shares are significantly cheaper no matter how you look at them.
    • Ultimately, deciding between the two is pretty straightforward; investors who want safety should stick to Nike but it looks like the potential upside for Deckers is much bigger.
  • Campbell Continues To Falter
    CPB Today, 7:52 AM Lester Goh 1 Comment

    Summary

    • In a prior piece, I talked about how Campbell was stuck between a rock and a hard place - declining sales, debt piling up, dividends and buybacks may be threatened.
    • After another quarter, the situation seems to be improving - sales are recovering, albeit at a slow pace.
    • Debt continues to pile up, which might be dangerous considering a rate hike seems likely in the near future.
    • Management needs to focus more on the business for the moment - stemming the decline of revenues, improving margins and paying down debt, instead of appealing to shareholders.
    • Eventually, something has got to give, I remain bearish.
  • Why A Beaten Down Silver Wheaton Can Be A Good Long-Term Investment
    SLW Today, 7:50 AM Renu Singh 1 Comment

    Summary

    • Silver Wheaton's latest results were below the mark, aggravating the company's weak financial performance.
    • Driven by industrial demand and silver production, the price of the metal is expected to increase, and this will have a positive impact on Wheaton.
    • Being a streaming company, Wheaton doesn't need to invest in mines, which is an advantage since it can focus its cash flow on signing more mining agreements.
    • Wheaton will also benefit from an expected uptick in gold pricing, as it has bought additional gold streams from Vale.
  • Monday's Rally Was News Oriented - Cramer's Mad Money (3/30/15)
    HZNP, HPTX, ASPX Today, 7:36 AM SA Editor Mohit Manghnani 2 Comments

    Summary

    • The two streams of money flowing in.
    • Buy Lululemon Athletica.
    • Organic food has a demand-supply mismatch.
  • Penn Virginia: Weak Balance Sheet And Weak Asset Base
    PVA Today, 7:30 AM Omar Jama 2 Comments

    Summary

    • Risk/Reward is poor for HY Bonds and Equity.
    • M&A unlikely as valuation too high, Assets not proven.
    • Negative bias to 2016 production despite ongoing negative free cash flow.
  • Warren Buffett Increases Berkshire Hathaway's Stake In IBM - Let's Analyze It
    IBM Today, 7:20 AM Mycroft 13 Comments

    Summary

    • We will analyze comments made by Mr. Buffett on IBM.
    • Let us give an opinion as to why IBM is having so many problems.
    • We will also try to identify what Mr. Buffett likes about IBM.
  • Seadrill And Transocean Will Lead The Rig Market Recovery
    RIG, SDRL Today, 7:16 AM Rupert Hargreaves 1 Comment

    Summary

    • Transocean and Seadrill are restructuring their drilling fleets.
    • Both companies are postponing the delivery of rigs.
    • Prudent fleet management will put the two companies at the forefront of the industry recovery.
  • Dollar General: Focus On Low-Cost Items, Store Optimization, And A Cheap Valuation Make It A Good Investment
    DG Today, 7:10 AM Harsh Singh Chauhan Comment!

    Summary

    • Most of Dollar General's customers belong to the low-income group, so the company is doing the right thing by increasing its focus on $1-$5 items.
    • Dollar General is optimizing its stores in order to eliminate redundancies, apart from focusing on lifecycle remodels to improve margin performance.
    • Dollar General is cheaper by a big margin when compared to its rivals, but its earnings growth is expected to outpace the industry.
  • Nucor: Weighing The Pros Against The Cons
    NUE Today, 7:04 AM Anup Singh Comment!

    Summary

    • Nucor recently cut its guidance by a big margin as increasing imports in the U.S. steel market have pressurized prices.
    • Nucor is seeing slow demand because of the weakness in the energy market, but the flipside is that this might spur manufacturing activity due to low costs.
    • Nucor has been able to improve its key financial metrics in recent months, and growth in the non-residential construction market will help it mitigate weakness in other areas.
    • Nucor is cheaper than its peers, but its bottom line growth is expected to be way better than the industry average.